PetaGene is expanding further into South Asia and other regions by naming Dubai-based Alliance Global as its exclusive partner in several countries.
Though Meehan was cautious on Waters in the near term, he provided a favorable outlook on Thermo Fisher Scientific.
By participating in the project, the company, located in Tokyo, hopes to improve its cloud-based data management services while winning over new customers.
Chipscreen is developing a small molecule inhibitor of key serine-threonine kinases involved in tumor angiogenesis, cell mitosis, and microenvironment inflammation.
In PLOS this week: missense variant linked to hereditary leukodystrophy in dogs, genetic variants associated with drug-induced interstitial lung disease, and more.
The company was originally founded as a spinoff from Korean genomic services provider Macrogen to offer direct-to-consumer genomic rare disease screening tests.
Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.
The company claims that certain Illumina sequencers infringe its US Patent No. 9,944,984, "Methods and Compositions for Efficient Base Calling in Sequencing Reactions."
In PNAS this week: cell line to assay myotonic dystrophy type 1 therapies, gene involved in rice architecture, and more.
A new study catalogues the genome and evolutionary history of the oak family, UPI reports.
Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.
A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.
In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.